What is US Patent 9,732,075 for?
U.S. Patent 9,732,075 is associated with daridorexant, a medication used to treat insomnia. The patent specifically covers compounds that act as dual orexin receptor antagonists [1]. Orexin is a neuropeptide that plays a role in promoting wakefulness, and blocking its receptors can help reduce the drive to stay awake [2].
When does the patent for daridorexant expire?
The expiration date for U.S. Patent 9,732,075 is September 17, 2030 [1]. This patent is listed in the U.S. Food and Drug Administration's (FDA) Orange Book for daridorexant [3].
Can generic versions of daridorexant be made before the patent expires?
Generally, generic versions of a drug cannot be manufactured or marketed in the United States before the expiration of relevant patents, such as U.S. Patent 9,732,075, unless those patents are successfully challenged or invalidated [1][3]. The Hatch-Waxman Act provides a framework for generic drug approval, but it respects patent protections.
What are daridorexant's orexin receptor targets?
Daridorexant is a dual orexin receptor antagonist. This means it blocks both the orexin 1 receptor (OX1R) and the orexin 2 receptor (OX2R) [1][2]. This dual action is believed to be key to its efficacy in treating insomnia by reducing the drive for wakefulness.
Who developed daridorexant?
Daridorexant was developed by Idorsia Pharmaceuticals [4]. It is marketed under the brand name Quviviq [5].
What is daridorexant used to treat?
Daridorexant is indicated for the treatment of insomnia in adults [5]. It is designed to improve sleep onset and sleep maintenance [2].
How does daridorexant work?
Daridorexant functions by blocking the activity of orexin, a neurotransmitter that promotes wakefulness. By inhibiting the orexin receptors OX1R and OX2R, daridorexant reduces the brain's signaling to stay awake, thereby facilitating sleep [1][2].
What are the clinical findings for daridorexant?
Clinical trials have demonstrated that daridorexant can improve sleep onset and sleep maintenance in adults with insomnia. For example, in one study, patients taking daridorexant showed statistically significant improvements in latency to persistent sleep and total sleep time compared to placebo [4].
What is the commercial status of daridorexant?
Daridorexant, marketed as Quviviq, was approved by the FDA in January 2022 and launched shortly after [4][5]. Its commercialization is managed by Idorsia Pharmaceuticals [4].
What other drugs target orexin receptors?
Other medications that target orexin receptors include suvorexant (Belsomra) and lemborexant (Dayvigo), which are also dual orexin receptor antagonists used for insomnia [6][7].
Sources:
[1] DrugPatentWatch.com
[2] Quviviq Prescribing Information
[3] FDA Orange Book
[4] Idorsia Pharmaceuticals Press Releases
[5] U.S. Food and Drug Administration (FDA)
[6] Belsomra Prescribing Information
[7] Dayvigo Prescribing Information